Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Issue 9 (September 2015)

• Record Type: Journal Article
• Authors: Borch, Troels H.; Donia, Marco; Andersen, Mads H.; Svane, Inge M.
• Is Part Of: Drug discovery today. Volume 20:Issue 9(2015)
• Page Start: 1127
• Page End: 1134
• Publication Date: 2015-09
• Subjects: Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2015.07.003
• Languages: English
• ISSNs: 1359-6446

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">We review PD-1 pathway blockade in the context of immunotherapy of cancer.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">PD-1 and its ligands are excellent targets in anti-cancer therapy.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Anti-PD-1 and anti-PD-L1 antibodies have shown promising clinical activity.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Two anti-PD-1 antibodies are FDA-approved for treatment of metastatic melanoma.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">Combination therapy holds the promise of producing stronger anti-cancer effects.</p> </list-item> </list> </p> </sec> </abstract>